title: Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
abstract: OBJECTIVE
  To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas.
  
  
  METHODS
  All patients with sarcoma or carcinosarcoma of gynecologic origin and documented recurrence or persistence of disease after appropriate surgery, radiation therapy and/or chemotherapy were recruited to the study. All patients were ambulatory and had measurable disease that could be documented on CT scan. Patients were started on 200 mg/day of thalidomide orally every night and escalated by 100-200 mg every 7 to 14 days. The length of the treatment was separated into 2 cycles with the first 84 days defined as the first cycle and the next 56 days as the second cycle. Common Toxicity Criteria were used to record toxicities. Because thalidomide was postulated to induce cytostasis, the end-points were progression-free and overall survival in this mixed group of patients.
  
  
  RESULTS
  Seventeen patients were enrolled. The drug was not well tolerated because of constipation, fatigue, worsening performance status, drowsiness and sleepiness. The total dosage of medication given to each patient ranged from 3200 mg to 40,500 mg. The maximum dosage reached in each patient ranged from 300 mg to 750 mg, with the total time of treatment ranging from 13 to 99 days. All patients had progression of disease with a median progression-free survival time of 1.84 months (CI 1.54-2.79 months) and a median overall survival of 6.64 months.
  
  
  CONCLUSIONS
  Thalidomide has no activity in patients with advanced or recurrent gynecologic sarcomas and was not well-tolerated. The overall survival was <7 months. The progression-free survival was <3 months, and, since the therapy was not tolerated well, we unanimously decided to close the study at this point. Despite the poor result, we still believe in the strategy of anti-angiogenesis and will continue to pursue other potential treatment options using the same concept.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA. dek2001@med.cornell.edu
authors.forename: D
authors.initials: D
authors.lastname: Yi-Shin Kuo
authors.forename: Patrick
authors.initials: P
authors.lastname: Timmins
authors.forename: Stephanie V
authors.initials: SV
authors.lastname: Blank
authors.forename: Abbie L
authors.initials: AL
authors.lastname: Fields
authors.forename: Gary L
authors.initials: GL
authors.lastname: Goldberg
authors.forename: Anthony
authors.initials: A
authors.lastname: Murgo
authors.forename: Paul
authors.initials: P
authors.lastname: Christos
authors.forename: Scott
authors.initials: S
authors.lastname: Wadler
authors.forename: Carolyn D
authors.initials: CD
authors.lastname: Runowicz
mesh_terms: D000284:Administration, Oral; D002296:Carcinosarcoma / Q000188:drug therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide